ERPY - ERPY STOCK NEWS

ERYTECH Pharma will host a conference call on March 9, 2021, at 2:30 PM CET to discuss operational highlights for the fourth quarter and full year 2020. The call will be accessible via various teleconferencing numbers, with a Conference ID of 8861234#. Additionally, the event will be available as a webcast and can be followed live online. ERYTECH is focused on innovative therapies for severe cancers, notably through its lead candidate, eryaspase, currently in clinical trials for pancreatic cancer and triple-negative breast cancer.

ERYTECH Pharma announced its participation in virtual investor conferences in March 2021. CEO Gil Beyen will present at the Cowen Annual Health Care Conference from March 1-4, participating in a panel discussion on March 2 at 9:50 am ET, and will conduct one-on-one meetings. Additionally, at the H.C. Wainwright Global Life Sciences Conference on March 9-10, a pre-recorded presentation will be available for attendees. The company focuses on developing innovative therapies like eryaspase for treating severe cancers.

ERYTECH Pharma, a clinical-stage biopharmaceutical company, announced its participation in the 2021 BIO CEO & Investor Conference. CEO Gil Beyen will present a corporate overview and engage in one-on-one meetings from February 16 to 18, 2021.

The conference will be held virtually, with a pre-recorded presentation available for registered attendees from February 16 through March 14. ERYTECH is developing red blood cell-based therapeutics, including its lead product candidate, eryaspase, which targets cancer cell metabolism.

ERYTECH Pharma announced that the TRYbeCA-1 Phase 3 trial, evaluating eryaspase in second-line pancreatic cancer, will proceed to its final analysis as recommended by the Independent Data Monitoring Committee (IDMC). The trial is fully enrolled with 512 patients, exceeding the target of 482. No safety issues were identified, consistent with prior reviews. The final analysis is expected in Q4 2021, with the trial powered to detect a 27.5% reduction in death risk.

Voting Rights and Share Capital Update

As of January 31, 2021, the total number of shares in the capital of ERYP is 20,395,482, reflecting an increase from 20,057,562 on December 31, 2020. The total gross voting rights increased to 21,930,518 from 21,592,598 during the same period. Net voting rights also grew to 21,928,018 from 21,590,098. This information is provided in compliance with Article 223-16 of the French Autorité des Marchés Financiers regulations.

ERYTECH Pharma, a clinical-stage biopharmaceutical company, reported a cash position of €44.4 million ($54.4 million) at the end of December 2020. The company achieved key milestones in 2020 and is optimistic about 2021, anticipating results from four clinical programs led by its product candidate, eryaspase. Notable upcoming milestones include top-line results from the TRYBeCA-1 trial in second-line advanced pancreatic cancer and FDA feedback on approval paths for hypersensitive ALL. 2020 cash utilization was €56.3 million, a decrease from €73.2 million in 2019.

ERYTECH has announced the enrollment of the first patient in the Phase 1 trial of eryaspase for treating first-line pancreatic cancer. The trial, named rESPECT, aims to evaluate the safety of eryaspase in combination with modified FOLFIRINOX. Approximately 18 patients will participate, and the trial is conducted by Dr. Marcus Noel at Georgetown University. Results are anticipated to provide insights into the efficacy of this combination therapy, with a poster presentation scheduled at the ASCO GI symposium.

ERYTECH Pharma is set to present at the H.C. Wainwright Virtual BioConnect 2021 Conference. CEO Gil Beyen will deliver a pre-recorded corporate overview starting from January 11, available for on-demand viewing until January 14. ERYTECH, listed as ERPY on Nasdaq and Euronext, focuses on red blood cell-based therapies for severe cancers and orphan diseases. Its lead candidate, eryaspase, is in advanced clinical stages for treating pancreatic and triple-negative breast cancers. The company operates manufacturing facilities in Lyon and Princeton.

ERYP released its monthly update regarding the total number of voting rights and shares in its capital as of December 31, 2020. The report adheres to Article 223-16 of the French Autorité des Marchés Financiers. As of the end of December, the total number of shares composing the share capital stood at 17,956,115. The total of brut voting rights was 19,600,235, while net voting rights were 19,596,685. This data is essential for stakeholders monitoring the company's governance.